McKechnie Duncan (CIK 2062139) reported 12 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-07). Recent activity: Sell VRTX (1,541 shares), Sell VRTX (2,633 shares), Sell VRTX (2,437 shares), Sell VRTX (873 shares), Sell VRTX (2,500 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-07 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Sell | 1,541 | $799,779 |
| 2026-03-13 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Sell | 2,633 | $1.3M |
| 2026-03-06 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Sell | 2,437 | $1.2M |
| 2026-02-26 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Sell | 873 | $423,501 |
| 2026-02-26 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Sell | 2,500 | $1.2M |
| 2026-02-26 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Sell | 2,410 | $1.2M |
| 2026-02-19 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Sell | 1,148 | $555,345 |
| 2026-02-19 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Buy | 4,962 | $0 |
| 2026-02-18 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Sell | 2,283 | $1.1M |
| 2026-02-12 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Sell | 1,127 | $527,898 |
| 2026-01-26 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Buy | 4,720 | $0 |
| 2026-01-26 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | EVP, Chief Commercial Officer | Buy | 2,080 | $0 |
Source: SEC Form 4 filings · as of 2026-07-07